Restoring Calm. Reclaiming Lives.

Stimalia develops the first bioelectronic medical device for PTSD, transforming trauma care through minimally invasive neuromodulation that directly addresses the body's dysregulated stress response.

The Crisis

PTSD affects 24 million adults across Europe and the US, costing €350 billion annually. Over 50% remain symptomatic despite current therapies. Medications cause systemic side effects. Psychotherapy is time-intensive. Nerve blocks fade within weeks. Patients suffer persistent disability, opioid dependence, and elevated suicide risk.

Our Innovation

We've engineered a revolutionary grain-of-rice-sized, battery-free percutaneous bioelectronic implant. Wirelessly activated, it delivers sustained inhibition of pathological sympathetic hyperactivity, the nervous system overdrive driving PTSD symptoms. Unlike temporary nerve blocks, our approach provides continuous, adjustable, fully reversible therapy without surgery, leads, or systemic side effects.

Why It Works

Built on proven clinical evidence: 70-80% responder rates from stellate ganglion block studies, Level-I RCT validation, and real-world effectiveness across 1,293 patients. We're translating that proven mechanism into durable, patient-centric bioelectronic therapy and category disruption in PTSD treatment.

Market Opportunity

€2.3 billion PTSD therapy market. Platform extends to chronic pain and autonomic dysfunction, unlocking €15 billion peripheral neuromodulation opportunity.

Our Team

Founded by neuromodulation pioneer Pascal Doguet, PhD (CTO; 300+ patents), MedTech entrepreneur Olivier Ménage, PharmD (CEO; 25+ years), and neurovascular expert Sylvain d'Amico, MSc (CCO; Boston Scientific, Stryker, Penumbra). Supported by world-class scientific advisors.

STIMALIA

Org chart

Teams

Offices

STIMALIA

Org chart

Teams

Offices

Related companies